Bio-Path Holdings

Bio-Path Holdings, Inc. is a biotechnology company, which engages in the development of therapies for acute myeloid leukemia (AML) and chronic myeloid leukemia (CML). Its product pipeline includes Prexigebersen, BP1002, and BP1003. The company was founded by Peter Nielsen, Douglas P. Morris, Gabriel Lopez-Berestein and Ana Tari Ashizawa on May 10, 2007 and is headquartered in Bellaire, TX.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Bio-Path Holdings reports positive Q1 results and advances key drug programs

Bio-Path Holdings (BPTH) showcased progress in key drug programs, financial stability, and global patent expansion. While facing regulatory and competitive challenges, the company is well-positioned to capitalize on opportunities in the biopharmaceutical sector. Optimism for future growth and innovation was expressed by CEO Peter Nielsen during the earnings call.

Bio-Path reports Q2 progress with prexigebersen and promising trials

Bio-Path Holdings showcased progress in clinical trials and financial management, emphasizing innovation and commitment to revolutionize cancer treatment.
While facing challenges in commercialization and market competition, the company's strong dedication to personalized medicine and promising trial results present growth opportunities.
With a focus on leveraging molecular biomarkers and advancing pipeline candidates, Bio-Path is strategically positioned to drive future success in the oncology space.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Bio-Path Holdings, Inc. is a biotechnology company, which engages in the development of therapies for acute myeloid leukemia (AML) and chronic myeloid leukemia (CML). Its product pipeline includes Prexigebersen, BP1001-A, BP1002, and BP1003. The company was founded by Peter H. Nielsen, Douglas P. Morris, Gabriel Lopez-Berestein and Ana Tari Ashizawa on May 10, 2007 and is headquartered in Bellaire, TX.

Bio-Path Holdings Inc (BPTH) CEO Peter Nielsen on Q2 2020 Results - Earnings Call Transcript

Conference Call to be Held Today at 8:30 A.M. ET Conference Call to be Held Today at 8:30 A.M. ET

Bio-Path Holdings Reports Second Quarter 2020 Financial Results

Combination of Prexigebersen, Decitabine and Venetoclax Is Expected to Have Several Potential Pathways to Registration Combination of Prexigebersen, Decitabine and Venetoclax Is Expected to Have Several Potential Pathways to Registration

Bio-Path Holdings Announces First Patient Dosed in Amended Stage 2 of the Phase 2 Clinical Trial Evaluating Prexigebersen in Acute Myeloid Leukemia

HOUSTON, Aug.  07, 2020  (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ: BPTH), a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced that it will host a live conference call and audio webcast on Friday, August 14, 2020 at 8:30 a.m. ET to report financial results for the second quarter ended June 30, 2020 and to provide a business overview.

Bio-Path Holdings to Announce Second Quarter 2020 Financial Results on August 14, 2020

Nielsen Hlds

Bio-Path Holdings, Inc. (BPTH) CEO Peter Nielsen on Q1 2020 Results - Earnings Call Transcript

Bio-Path Holdings Reports First Quarter 2020 Financial Results

To say the least, Bio-Path Holdings Inc. (NASDAQ: BPTH) stock has taken a beating in the past five years.

How Much Cash Can Bio-Path Burn?

On Friday, March 6, oncology drug development company Bio-Path Holdings Inc. (NASDAQ: BPTH) reported fiscal year 2019 results.

Are Limited Financing Options Punishing Bio-Path Stock?

HOUSTON, March  11, 2020  (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced that the Audit Committee of the Company’s Board of Directors approved the appointment of Ernst & Young LLP (“EY”) as the Company’s new independent registered public accounting firm, replacing former auditor, BDO USA, LLP (“BDO”).

Bio-Path Holdings Appoints Ernst & Young as New Auditor

What is it like to have a stock plunge 90% in less than a year and wipe out a huge amount of market capitalization?

How Delayed Drug Approval Is Punishing Bio-Path Stock

HOUSTON, Jan.  08, 2020  (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ: BPTH), a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, today provides an update from several clinical development programs and a 2020 business overview.

Bio-Path Holdings Provides Clinical Update and 2020 Business Outlook

Bio-Path (BPTH) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Bio-Path (BPTH) Upgraded to Buy: Here's What You Should Know

Combination of Prexigebersen and Decitabine Showed Encouraging Safety and Efficacy Results Combination of Prexigebersen and Decitabine Showed Encouraging Safety and Efficacy Results

Bio-Path Holdings Announces Successful Completion of Safety Testing in Stage 2 of Phase 2 Clinical Trial in Acute Myeloid Leukemia

HOUSTON, Nov.  25, 2019  (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (Nasdaq:BPTH), a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced the closing of its previously announced offering. In a registered direct offering priced at-the-market, Bio-Path issued and sold 808,080 shares of its common stock and warrants to purchase up to 606,060 shares of its common stock, at a combined purchase price of $9.90 per share and associated warrant, for aggregate gross proceeds of approximately $8.0 million.

Bio-Path Holdings Announces Closing of $8.0 Million Registered Direct Offering Priced At-the-Market

HOUSTON, Nov.  21, 2019  (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (Nasdaq:BPTH), a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced that it has entered into definitive agreements with several healthcare focused institutional investors for the issuance and sale in a registered direct offering of 808,080 shares of its common stock and warrants to purchase up to 606,060 shares of its common stock, at a combined purchase price of $9.90 per share and associated warrant, for aggregate gross proceeds of approximately $8.0 million.

Bio-Path Holdings Announces $8.0 Million Registered Direct Offering Priced At-the-Market

Phase 1 Clinical Trial to Evaluate Ability of BP1002, Targeting Bcl-2 Protein, to Treat Refractory/Relapsed Lymphoma and Chronic Lymphocytic Leukemia Patients Phase 1 Clinical Trial to Evaluate Ability of BP1002, Targeting Bcl-2 Protein, to Treat Refractory/Relapsed Lymphoma and Chronic Lymphocytic Leukemia Patients

Bio-Path Holdings Announces Clearance of Investigational New Drug Application for BP1002

Bio-Path (BTPH) earnings for the biotechnology company's third quarter of 2019 saw BTPH stock taking a wild ride on Friday.

Bio-Path Earnings: BPTH Stock Moves on Q3 Results

Bio-Path Holdings, Inc (BPTH) CEO Peter Nielsen on Q3 2019 Results - Earnings Call Transcript

Brings 25 Years of Experience in Business Development and Marketing Brings 25 Years of Experience in Business Development and Marketing

Bio-Path Holdings Appoints Martina Molsbergen to Board of Directors

HOUSTON, Sept.  03, 2019  (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ: BPTH), a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced that Peter H. Nielsen, Chief Executive Officer, will present a corporate overview at the upcoming H.C. Wainwright 21st Annual Global Investment Conference on Monday, September 9, 2019 at 3:25 p.m. ET in New York.

Bio-Path Holdings to Present at the H.C. Wainwright 21st Annual Global Investment Conference

HOUSTON, Aug.  26, 2019  (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced patient dosing in Bio-Path’s amended Phase 2 trial of prexigebersen for the treatment of acute myeloid leukemia (AML), as announced in March 2019.

Bio-Path Announces Patient Dosing in Amended Phase 2 Prexigebersen Trial in Acute Myeloid Leukemia

Bio-Path Holdings, Inc. (BPTH) CEO Peter Nielsen on Q1 2019 Results - Earnings Call Transcript

Bio-Path rocketed Monday after withdrawing its December offering for stocks and warrants. Bio-Path is working on a number of cancer treatments.

How This Highly Rated Biotech Stock Added To Its Meteoric Run

Bio-Path Holdings Inc.'s stock rocketed 48% in morning trade Monday, after the biotechnology company focused on cancer treatments filed to withdraw a common stock offering.

Bio-Path's stock rockets after withdrawal of stock offering

Bio-Path Holdings (BPTH) CEO, Peter Nielsen on Q4 2018 Results - Earnings Call Transcript

News for Bio-Path Holdings Stock (BPTH)